PHXM PHAXIAM THERAPEUTICS

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024

Article 223-16 of general regulation of French Autorité des Marchés Financiers

Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM)

Website :

DateTotal of shares composing the share capitalTotal of brut (1) voting rights



Total of net (2) voting rights



December 31, 20236 075 1056 226 9826 226 733
January 31, 20246 075 1056 227 0026 226 753
February 29, 20246 075 1056 226 9516 226 702
March 29, 20246 075 1056 226 9386 226 689
April 30, 20246 075 1056 226 9326 226 683
May 31, 20246 075 1056 226 9896 226 740
July 1, 20249 980 66810 132 59710 132 348
October 8, 202410 013 71910 165 84810 165 599
October 31, 202410 013 71910 165 84610 165 597

(1)   Gross voting rights number (or « theoretical » voting rights) is used as a basis for calculating the crossing of the threshold. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on the basis of all shares carrying the single and double voting rights, including shares without voting rights.

(2)   Without treasury shares.

Attachment



EN
08/11/2024

Underlying

PHXMPHAXIAM THERAPEUTICS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PHAXIAM THERAPEUTICS

 PRESS RELEASE
Free
PHXM PHAXIAM THERAPE...

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibil...

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" This event, organized in collaboration with Phage Canada and bringing together international experts, highlighted the growing interest in phage therapy and the urgent need for a reference method for phagogram on an international scalePHAXIAM phages demonstrated outstanding performance against clinical bacterial strains Lyon (France) – November 18, 2024, at 06:00 p.m. C...

4h / 33m 1 EN
 PRESS RELEASE
Free
PHXM PHAXIAM THERAPE...

PHAXIAM Reports Third-Quarter 2024 Financial Information

PHAXIAM Reports Third-Quarter 2024 Financial Information Cash and cash equivalents of €5.7 million as of September 30, 2024Execution of clinical strategy as planned, with the GLORIA global Phase II study initiation expected in the first quarter of 2025 Lyon (France), November 13, 2024, at 5:45 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today reports its financial results for the third quarter of 2024. "The third quarter of 2024 was marked by the steady execution of our clinic...

November 13, 2024 1 EN
 PRESS RELEASE
Free
PHXM PHAXIAM THERAPE...

Monthly information related to total number of voting rights and share...

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024 Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024 Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) Website : DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rightsDecember 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 ...

November 8, 2024 1 EN
 PRESS RELEASE
Free
PHXM PHAXIAM THERAPE...

Information mensuelle relative au nombre total de droits de vote et d’...

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024 Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024 Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation : Euronext Paris (Compartiment C - Code ISIN : FR001400K4B1 – Symbole : PHXM) Site web : DateNombre total d’actions composant le capital socialNombre total de droits de vote brut (1)Nombre total de droits de vote net (2)31 décembre 20236 075 1056 226 ...

November 8, 2024 1 EN
 PRESS RELEASE
Free
PHXM PHAXIAM THERAPE...

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORI...

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S. GLORIA, the world's 1st phase II phage therapy study in the treatment of Prosthetic Joint Infections (PJI) related to Staphylococcus aureusThe clinical protocol also being submitted to the European health authorities and the MHRA in the UKPatients recruitment scheduled to start in Q1 2025 for clinical data readout expected in Q3 2026 Lyon (France), November 04, 2024 – 6:00 pm CET - PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for se...

November 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch